Risk factors linked to distress in the pre-surgical and pre-chemotherapy phases. Do they have the same psychological basis? by Civilotti, Cristina et al.
P2-73
Risk factors linked to distress in the pre-surgical and pre-chemotherapy phases. Do they 
have the same psychological basis?
Cristina Civilotti 1 ,2, Efrem Sabatti3, Claudia Romano3, Francesca Facchi3, Gianluca Fogazzi3
1Department of Psychology, University of Turin, Turin, Italy, 2Edo ed Elvo Tempia Foundation, 
Biella, Italy, 3Sant'Anna Clinic Institute, San Donato Group, Brescia, Italy
Background
The main purpose of this study was to describe the women's experiences after having received a 
breast cancer diagnosis in terms of anxiety, depression and distress in two phases along the 
cancer journey: the pre-surgery phase and the pre-chemotherapy phase. Moreover, we tried to 
model predictors of distress in the two phases, using a cross-sectional methodology of the 
following variables: age, stage of the disease, education, employment status, level of anxiety and 
level of depression.
Method
The data were collected in the Breast Unit of the Istituto Clinico S. Anna, Brescia, Italy, via a 
routine psychological screening program. Of 227 consecutive patients, 196 gave consent and 
completed responses for the administration of three questionnaires: BDI-II (Beck et al., 1996), 
STAI (Spielberger et al. 1983) and PDI (Morasso et al., 1996). 106 patients were in Group-A 
(pre-surgery phase) and 90 patients were in Group-B (pre-chemotherapy phase). Anxiety, 
depression and socio-demo variables (age, education, employment status, stage of the disease) 
were entered in a stepwise multiple regression analysis to predict the perceived distress level.
Results
In Group-A, 48.2% of the women reported a significant level of anxiety and 38.5% reported at 
least a mild level of depression; in Group-B anxiety and depression were found respectively in 
44.3% and 37.3% of the sample. The mean of PDI score was 26.13 in Group-A (SD=9.13) and 
26.77 in Group-B (SD=8.39). In Group-A, the prediction model (F(2,92)=71.180, p<.001) showed 
anxiety and depression as significant predictors and accounted for approximately 60% of the 
variance of PDI scores. In Group-B, depression and age emerged as predictors, and this model 
(F(2,86)=71,798, p<.001) explained 62% of the variability in the PDI scores.
Conclusions
There were no differences between the mean of Group-A and that of Group-B in terms of anxiety, 
depression and distress. In both A and B groups, correlations were identified between the 
presence of distress and anxiety and depression, but not with socio-demographic variables. 
However, differences were noticed in the predictors of distress in the two phases: in the group-A, 
anxiety and depression were the components that emerged with greater strength in determining 
the perception of the level of distress. In the group-B the level of anxiety was excluded from the 
model and the predictive variables were depression and younger age.
Research Implications
Many progresses highlight the differences that occur at various steps of the disease, but many 
are still pursued in order to understand the complexity of human experience along the cancer 
journey, from the beginning to the later phase, such as survivorship or end of life. For future 
research, we underline the importance of a longitudinal perspective, as psychological distress 
has been shown to vary significantly during time and stages of the disease.
Clinical Implications
This study underlines how it is important to properly understand the psychological sufferance of a 
woman with breast cancer in order to provide changes in her care management during the 
cancer trajectory. In particular, this study demonstrates how the level of anxiety plays a different 
role in determining distress in the two phases studied: anxiety is more impairing right before the 
surgery, while in later phases seems to be more integrated and accepted by patients.
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